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Purpose of review 
To describe how to better identify frail multiple myeloma patients and to treat them appropriately. 
 
Recent findings 
Proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib, and immunomodulatory 
agents (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, have significantly improved 
the outcome of multiple myeloma patients in the last decade. However, both in clinical trials and in 
daily clinical practice, elderly multiple myeloma patients have shown lesser benefit. This is mainly 
due to less stringent use of proteasome inhibitors and IMiDs, increased toxicity, and subsequent 
early discontinuation of therapy in elderly. 
 
Summary 
Multiple myeloma typically affects elderly patients. Approximately one-third of patients are older 
than 75 years at diagnosis. Moreover, at least 30% are frail, both due to disease-related symptoms 
and (agerelated) decline in physical capacity, presence of comorbidities, frailty, polypharmacy, 
nutritional status, and cognitive impairment. Treatment regimens that are investigated in clinical 
trials for transplant-ineligible patients have largely been investigated in fit, rather than frail patients, 
the latter being typically excluded or highly underrepresented therein. Data on the feasibility and 
efficacy of current standards of care are therefore lacking in frail patients. Preliminary data suggest 
a higher toxicity and discontinuation rate, loss of efficacy, and impaired quality of life in frail 
patients. Geriatric assessment helps to identify frail patients according to their functional and 
cognitive status. Both the International Myeloma Working Group (IMWG)- frailty index and 
Revised Myeloma Comorbidity Index constitute recently proposed algorithms that easily identify 
intermediate-fit and frail patients. Ongoing and future clinical trials, specifically designed for frail 
patients, will hopefully define frailty-directed treatment selection.
INTRODUCTION 
The introduction of proteasome inhibitors and IMiDs combined with standard chemotherapy, has 
changed the management of multiple myeloma patients and has substantially extended both 
progression- free survival (PFS) and overall survival (OS), also in elderly patients [1]. However, the 
added value of proteasome inhibitors and IMiDs are generally less pronounced in the oldest patients 
more than 75 years of age, as has been shown in several clinical trials as well as population based 
registries (PBR) [2–4]. 
These data are highly relevant, because the global population is rapidly aging in all European 
countries. Particularly the population aged more than 80 years is expected to rise to almost triple 
[5]. The elderly population is highly heterogeneous, consisting of fit, intermediate-fit and frail 
patients. Geriatric impairment is prevalent in elderly patients, may not be easily detectable, but 
impacts patients’ ability to complete treatment. Identification of such impairment is important, as 
omitting geriatric assessment will result in the fact that intermediate- fit and frail patients receive 
regimens that were initially tested in fit patients. This may cause substantial toxicity, early treatment 
discontinuation, lower efficacy, and impaired quality of life (QoL) [6]. The aim of this review is to 
clarify how to better categorize older multiple myeloma patients, thereby identifying fit, 
intermediate-fit and frail cohorts and to treat them appropriately based on current available 
knowledge. 
 
Elderly patients more than 75 years of age have been shown to benefit from anti-multiple 
myeloma treatment; however, the benefit was less pronounced than in patients aged less than 
75 years 
Multiple myeloma accounts for 1% of all types of cancer and for 2% of all cancer deaths. These 
numbers represent approximately 13% of all hematological malignancies, and 20% of 
hematological malignancy-related deaths [4,7]. Multiple myeloma is a disease of the elderly 
reflected by a median age at diagnosis of approximately 70 years, with 35–40% of patients being 
older than 75 years [8]. For the past 10 years, the prognosis of elderly patients has improved due to 
the introduction and use of IMiDs (thalidomide, lenalidomide, pomalidomide) and proteasome 
inhibitors (bortezomib, carfilzomib and recently the oral proteasome inhibitor ixazomib). In first-
line treatment of transplantineligible patients, the addition of bortezomib to melphalan and 
prednisone (VMP) improved both PFS and OS, as compared to melphalan and prednisone alone, 
therefore VMP advanced to one standard of care in Europe [9,10]. Accordingly, the addition of 
thalidomide to melphalan and prednisone (MPT) resulted in superior PFS and OS as compared to 
melphalan and prednisone [11]. Recently, the results from the FIRST-trial showed superiority of 
lenalidomide/dexamethasone over MPT both with respect to PFS and OS [12]. Importantly, VMP 
and lenalidomide/dexamethasone result in a median OS of almost 5 years. When assessing patients 
at least 75 years of age, elderly patients were also found to benefit from VMP and lenalidomide/ 
dexamethasone, although this benefit was less pronounced than in patients less than 75 years. The 
median OS with VMP was 43.3 months vs. not reached in patients 75 or older and less than 75 
years, respectively [13]. Likewise, the median OS with lenalidomide/dexamethasone was 52.3 vs. 
60.9 months in patients 75 or older and 75 years or less, respectively [3].  
Also in PBR, reflecting real life, the eldest patients appear to benefit less: both in Italian and Dutch 
PBR, the OS of older patients at least 75 years was found to be similar over time, without an 
improvement in OS after the introduction of IMiDs and proteasome inhibitors after 2006 [4] 
(Verelst, personal communication). This lack of improvement does not seem to be explained by a 
biologically different, more aggressive disease in the elderly. Although data on cytogenetic analyses 
in the elderly patients are generally scarce [14] and differences in cytogenetic abnormalities have 
been observed between younger and older patients [15], there is currently no evidence of a higher 
incidence of biologically high-risk disease in the latter. The French Intergroupe Francophone du 
Mye´lome (IFM) showed that the incidence of t(4;14) was even decreased in patients more than 75 
vs. 66–74 and 65 years or less with 8.3, 10.9, and 14.3%, respectively. The incidence of del17p was 
similar in patients more than 75 vs. 66–74 and less than 65 years with 6.1, 5.9, and 6%, 
respectively. Data on del1p and ampl1q were not available [16]. In addition, no increase in the 
percentage of prognostic adverse hypermethylation of the tumor modulating genes GPX3, RBP1, 
SPARC, and TGFBI was found with age [17].  
The lesser benefit of treatment in the very elderly might be better explained by the fact that in 
general practice the majority of elderly patients do either not receive therapy, or therapy is given but 
without the addition of proteasome inhibitors or IMiDs or with a lower dose of novel agents [18]. 
That this fact at least partly explains the difference in outcome between clinical trial and PBR is, 
indeed, supported by several observations showing that if novel therapy is given to the elderly 
outside of clinical trials, there is an increase in OS, even in the oldest patients. Data analysis of 
elderly patients actually receiving lenalidomide and/or bortezomib from the Mayo Clinic (89% of 
all patients used novel agents during the time period 2006–2010 vs. 29% in the period 2001–2005) 
showed an increase in OS over time, specifically in those aged over 65 years (median OS 5 vs. 3.2 
years). Improved survival was also seen in those over 75 years of age [19,20]. Of course such data 
analyses are biased by the fact that the reasons for either or no treatment are unknown; however, 
these data indicate that at least a subgroup of elderly patients benefit from novel therapies. The 
challenge therefore is to determine who will benefit from therapy, as the higher incidence of organ 
dysfunction, leading to toxic effects of standard treatment regimens requiring treatment 
discontinuation probably negatively affects the benefit of treatment and might even be deleterious. 
Indeed, a meta-analysis of 1435 patients at least 65 years treated in four European clinical trials 
showed that the risk of death was increased in patients at least 75 years, in patients with renal 
failure, in those who experienced grade 3–4 infections, cardiac or gastrointestinal adverse events 
during treatment and in those who required drug discontinuationdue to adverse events. This 
increased risk was restricted to the first 6 months after occurrence of adverse events or drug 
discontinuation and declined over time [6]. This supports the need for tailored personalized 
medicine in elderly patients.  
 
Are there tools available to define the subpopulation of elderly multiple myeloma patients 
who will benefit from treatment?  
Since there is an urgent need to determine in whom effective antimyeloma therapy is feasible and in 
whom treatment will not only fail but might even compromise patients’ QoL, comprehensive 
geriatric assessment (CGA) tools have been used to identify patients’ general health status, 
including functional, cognitive, social, nutritional, and psychological parameters. These have been 
found to predict OS and adverse events during chemotherapy [21,22]. However, extensive data on 
the value of CGA in multiple myeloma patients are as yet incommensurate. Recently, the 
International Myeloma Working Group (IMWG) retrospectively assessed the IMWGfrailty index. 
This index is based on age (_75, 75–80, >80 years, score 0, 1, 2, respectively), Charlson 
Comorbidity Index (CCI; _1 or _2, score 0 or 1) and (Instrumental) Activities Daily Life score 
(ADL >4 or _4, score 0 or 1, instrumental activities of daily living (IADL) >5 or _5, score 0 or 1), 
and was found to predict nonhematological toxicity in 869 patients at least 65 years treated within 
three randomized clinical trials. Frail patients (score _2) had a 1.8 times higher discontinuation rate 
as compared to fit patients (score 0). In a multivariate analysis frailty [hazard ratio (HR) 1.64, 1.24–
2.17], ISS III (HR 1.49, 1.17–1.89) and high-risk cytogenetics by fluorescence in situ hybridization 
analysis defined as del17p, t(4;14) or t(14;16) (HR 1.75, 1.38–2.22) equally predicted PFS, whereas 
for OS, the HR increased most with frailty (HR 3.11, 1.97–4.90) as compared to ISS III (1.77, 1.26–
2.63 and high-risk cytogenetics (1.83, 1.26–2.63) [23&]. Importantly, in patients less than 75 years, 
frail and intermediate-fit patients were found in 17 and 44%, respectively, revealing that 
comorbidities also occur in ‘younger’ cohorts and suggesting that frailty scores are of added value 
to patients’ numerical age. The IMWG-frailty index has been validated in the IMF FIRST-trial 
comparing lenalidomide/dexamethasone continuously, lenalidomide/dexamethasone for 18 and 
MPT for 12 cycles. However, as the investigators did not assess the ADL and IADL, they used the 
EQ5D instead and confirmed an inferior outcome in frail vs. fit patients: the median PFS was 20.3 
vs. 43.7 months and median OS 52.3 months vs. not reached, respectively [23&]. Additional 
preliminary analyses from a Dutch HOVON study also support the prognostic value of the IMWG-
frailty index [24,25&].  
The most extensive prospective validation of the IMWG-frailty index was performed by Engelhardt 
et al. in a German cohort of newly diagnosed multiple myeloma patients. Moreover, the IMWG-
frailty index was compared with the Revised Myeloma Comorbidity Index (R-MCI) and other well 
known other comorbidity indices, such as CCI, Hematopoietic- Cell-Transplantation Comorbidity 
Index, and Kaplan Feinstein Index (KFI). Validation of the IMWG-frailty index in this prospective 
cohort demonstrated a 3-year-OS of 91%, 77% and 47% for fit, intermediate-fit and frail patients, 
respectively. The CCI, Hematopoietic-Cell-Transplantation Comorbidity Index, Kaplan Feinstein 
Index and the RCMI also defined fit and frail patients with distinct PFS and OS. The most 
pronounced differences in PFS and OS were found using the IMWG-frailty indes, CCI and R-MCI. 
As the CCI is included in the IMWG-frailty index, the latter and R-MCI were proposed for future 
frailty measurements, which is ongoing in a joint European Myeloma Network collaboration 
[26&&]. Subsequently, the value of the R-MCI was shown in 801 consecutive German multiple 
myeloma patients, this cohort being examined within a training and validation set. As multivariate 
analysis had determined renal, lung, Karnofsky performance Status (KPS) impairment, frailty, and 
age as independent risk factors for OS and high-risk cytogenetics to complement this R-MCI, these 
parameters were included in the weighted R-MCI, allowing identification of fit [R-MCI 1–3 
(n¼247, 30.8%)], intermediate- fit [R-MCI 4–6 (n¼446, 55.7%)], and frail patients [R-MCI 7–9 
(n¼108, 13.5%)]: these subgroups showed median OS rates of 10.1, 4.4, and 1.2 years, respectively. 
Advantages of the R-MCI are its accurate assessment of patients’ physical conditions and simple 
clinical applicability [27&&]. Both the IMWG-frailty index and R-MCI have demonstrated validity 
as straightforward prognostic instruments in large clinical studies and patients cohorts treated 
according to current standards. As determination of comorbidity, frailty, and disability evaluation in 
multiple myeloma can be time-consuming, both the IMWG-frailty index and the R-MCI have been 
implemented within web-based technology applications, which allows to perform the scores 
expeditiously (http://195.88.6.191/Frailtyscore/Geriatric. asp 
andwww.myelomacomorbidityindex.org). These data showing the association between the IMWG-
frailty score and R-MCI with clinical outcome underscore the importance of CGAs in the 
identification of intermediate-fit and frail patients. However, as treatment has not been modified 
according to the comorbidity index results, the next step is to include these indexes in prospective 
randomized clinical studies designed to adapt the therapeutic approaches.  
Furthermore, it is important to investigate whether current indexes can be improved further. In both 
the Dutch HOVON study and German studies the value of objectively measured functional geriatric 
assessments, such as gait speed, handgrip strength, ‘Timed Up and Go’-test, physicians’ and 
patients’ rating of fitness and others, are determined. In addition, more detailed information on 
nutrition and mental status are currently investigated. Finally, the value of biomarkers reflecting 
biological age, such as the senescence marker p16INK4a [28] and sarcopenia are explored 
[24,25&].  
 
How to treat elderly multiple myeloma patients in clinical practice? 
 There is evidence, that in patients at least 65 years, and especially in those at least 75 years, the 
toxicity of antimyeloma treatment and subsequently the discontinuation rate is higher, negatively 
affecting outcome. On the other hand, as described above, increasing treatment possibilities paved 
the way for improving the outcome also of elderly multiple myeloma patients. Given the first data 
on the predictive value of geriatric scores to define fit, intermediate- fit, and frail patients 
determined by simple geriatric assessment and scores (e.g. IMWG-frailty index, R-MCI), these 
should be implemented in clinical practice. As yet, there are no RCT results available that 
prospectively investigate the clinical outcome with and without antimyeloma treatment adaptions 
according to these assessments. The UK MRC, IFM, HOVON, and German DSMM study groups 
will or have already initiated studies based on the outcome of the IMWG-frailty index and R-MCI.  
Awaiting the result of these studies, based on the results of the Italian, French, German and Spanish 
clinical trials in which also patients more than 75 and patients more than 80 years of age (by 
definition intermediate-fit and frail, respectively, according to the IMWG-frailty index) were 
included and from preliminary data of the HOVON 123 study trial, practical guidelines can already 
be given (Table 1) [3,6,8,13,29&&,30–33]. Concerning VMP, the PETHEMA study group 
investigated a ‘VMP light regime’ with 5 cycles of once-weekly dosing of bortezomib following the 
first cycle of twice-weekly dosing, followed by 3 years of maintenance with bortezomib (either in 
combination with prednisone or thalidomide) [2,33]. The GIMEMA study group investigated 
bortezomib maintenance every 2 weeks, in combination with thalidomide, for 2 years following 
induction with an intense VMPT induction [30]. From the PETHEMA GEM05 study, it can be 
concluded that a limited, less intense induction, followed by maintenance, results in a comparable 
OS of 61.3 months vs. 61 months, respectively (even though being no head-to-head comparison). 
Moreover, toxicity was limited allowing a higher cumulative dose of bortezomib. The incidence of 
severe peripheral neuropathy (PNP) was significantly reduced from 14% in VISTA to 7%. 
Accordingly, the discontinuation rate due to SAEs was lower as compared to VISTA (17% vs. 
34%) [2,33]. From the GIMEMA MM03-05 study, it was concluded that maintenance with 
bortezomib was feasible; during maintenance: only 4% of patients developed grade 3 PNP, and no 
grade 4 PNP was reported [30]. Preliminary results from the HOVON 123 trial showed that in frail 
patients, nine cycles of adjusted VMP were feasible in only 54%; however, six cycles were 
achieved in 69%. Moreover, overall response and VGPR or better were comparable after six and 
nine cycles [25&]. In view of these results a shorter induction therapy followed by maintenance 
therapy is an attractive alternative in frail patients, in order to not only make antimyeloma therapy 
feasible but also maintain its efficacy.  
Concerning lenalidomide/dexamethasone, Hulin et al. [3] showed that by decreasing the dose of 
dexamethasone from 40 to 20 mg/week, lenalidomide/ dexamethasone was well tolerated without 
additional toxicity in patients more than 75 years of age. The treatment duration, exposure for more 
than 2 years and discontinuation rate in patients 75 or less and more than 75 years were comparable 
with 20 vs. 24 months, 35 vs. 41% and 26 vs. 21%, respectively [3].  
 
CONCLUSION 
The growing number of elderly multiple myeloma patients is increasing and thereby the need for 
practical strategies to recognize and appropriately manage frail patients. The efficacy and safety 
results suggest that full-dose can be applied in fit patients, whereas reduced therapy is preferred in 
frail patients (Table 1). Awaiting the results of clinical trials specifically designed for intermediate-
fit and frail patients, practical guidelines have been published that can be used to personalize 
therapy in elderly patients [7,8]. In order to realize continuation of treatment by minimizing 
toxicity, we propose the algorithm that is deduced from these guidelines and from myeloma expert 
opinions (Table 1) [7,34].  
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Table 1. Patient-frailty index and frailty index-defined risk factor assessment via International Myeloma 
Working Group-frailty index and Revised Myeloma Comorbidity Index, suggesting consideration of treatment 
adjustment based on patient fitness 
 
Patient risk factors 
Age >75 years 
Mild, moderately, or severely frail (patients who need help with either household tasks, personal care, 
or are completely dependent) 
Comorbidities (pulmonary, renal, cardiac, and hepatic dysfunction) 
And/or 
Preferably with (a) IMWG-frailty index1 and/or (b) R-MCI2 define fit, intermediate-fit, and frail 
patients, in order to consider to adapt antimyeloma therapy; fit level 0, intermediate fit level -1, and 
frail level -2. 
Frailty index risk factors 
IMWG frailty index1 0 1 1 + occurrence of grade 
3–4 hematological AE  
 
≥2 
R-MCI2 1–3 4–6 7–9  
Dose level 0  -1 -2 -2 
Treatment doses  Level 0 Level -1 Level -2 
Prednisone  2 mg/kg days 1–4 of 
a 4–6 week cycle  
60 mg/m2 days 1–4 
of a 6 week cycle 
1 mg/kg days 1–4 of 
a 4–6 week cycle 
30 mg/m2 days 1–4 
of a 6 week cycle 
0.3–0.5 mg/kg days 1–4 of a 
4–6 week cycle 
10–15 mg/m2 days 1–4 of a 6 
week cycle 
Dexamethasone  
 
40 mg day 1, 8, 15, 
22 of a 28-day cycle 
20 mg day 1, 8, 15, 
22 of a 28-day cycle 
10 mg day 1, 8, 15, 22 of a 
28-day cycle 
Melphalan  0.25 mg/kg days 1–4 
of a 4–6 week cycle 
9 mg/m2 days 1–4 of 
a 6 week cycle 
0.18 mg/kg days 1–4 
of a 4–6 week cycle 
7.5 mg/m2 days 1–4 
of a 6 week cycle 
0.13 mg/kg days 1–4 of a 4–6 
week cycle  
5 mg/m2 days 1–4 of a 6 
week cycle 
Thalidomide  100 (–200) mg/day  50 (–100) mg/day  50 mg qod (–50 mg/day) 
Lenalidomide 
 
25 mg days 1–21 of 
a 28-day cycle  
15 mg days 1–21 of 
a 28-day cycle  
10 mg days 1–21 of a 28-day 
cycle 
Pomalidomide  
 
4 mg days 1–21 of a 
28-day cycle  
3 mg days 1–21 of a 
28-day cycle 
2 mg days 1–21 of a 28-day 
cycle 
Bortezomib  
 
1.3 mg/m2 twice 
weekly  
Day 1, 4, 8, 11 every 
3 weeks 
1.3 mg/m2 once 
weekly 
Day 1, 8, 15, 22 
every 5 weeks 
1.0 mg/m2 once weekly 
Day 1, 8, 15, 22 every 5 
weeks 
Carfilzomiba  20 mg/m2 day 1, 2, 
8, 9, 15, 16 cycle 1, 
27mg/m2 cycle 2 
every 3 weeks 
20 mg/m2 cycle 1  
27 mg/m2 cycle 2, 
day 1, 8, 15, every 3 
weeks 
20 mg/m2 day 1, 8, 15, every 
4 (5) weeks 
Ixazomib  
 
4mg day 1, 8, 15, 
every 4 weeks 
3mg day 1, 8, 15, 
every 4 weeks 
2.3 mg day 1, 8, 15, every 
4 weeks 
Daratumumaba  
 
16 mg/kg bw cycle 
1–8: weekly; 
cycle 9–24: day 
1þ15, from 
week 25: every 4 
weeks 
16 mg/kg bw cycle 
1–8: weekly; cycle 
9–24: day 1þ15, 
from week 25: 
every 4 weeks 
 
16 mg/kg bw cycle 1–8: 
weekly; cycle 9–24: day 
1þ15, from week 25: every 4 
weeks 
Elotuzumabb  
 
10 mg/kg day 1, 8, 
15, 22, cycle 1+2, 
from cycle 3: day 
1+15 
10 mg/kg bw day 1, 
8, 15, 22, cycle 1+2, 
from cycle 3: day 
1+15 
10 mg/kg bw day 1, 8, 15, 22 
cycle 1+2, from cycle 3: day 
1+15 
 
Panobinostat  
 
20mg day 1, 3, 5, 8, 
10, 12 every 4 weeks 
15mg day 1, 3, 5, 8, 
10, 12 every 4 weeks 
10mg day 1, 3, 5, 8, 10, 12 
every 5 weeks 
 
In the Endeavor study the dose of carfilzomib was 56mg/m2, with 17% of patients of 75 years or older. No dose 
modification was applied. In the Aspire study where carfilzomib was combined with lenalidomide a lower dose of 
27mg/m2 was given, also not adapted according to age. 
1 http://195.88.6.191/Frailtyscore/Geriatric.aspx. 
2 http://www.myelomacomorbidityindex.org/en_about.html. 
AE, adverse event; IMWG, International Myeloma Working Group; R-MCI, Revised Myeloma Comorbidity Index; 
qod: every 2 day; cy: cycle, d: day, bw: body weight. 
a +. 
b: No known dose adaptation in elderly and/or frail patients reported. 
https://www.croh-online.com/article/S1040-8428(18)30014-3/abstract 
